quality control review & editing services

Delivering an unparalleled attention to detail

Woman pointing to a computer monitor and writing on a paper

Detailed and comprehensive quality control (QC) reviews (or data verification reviews) and editing are an integral part of the production lifecycle of a document, rather than a one-off step in the development process. Mistakes and inconsistencies in a document can call into question the validity of the content or result in an incorrect interpretation of the data.

ProPharma’s team of seasoned QC reviewers/editors provides quality review and editing services across a wide array of documents and therapeutic areas.

Ready to Speak to a Quality Control Reviewer/Editor?

Quality Control Review/Editing Services

ProPharma QC reviewers/editors perform targeted or comprehensive quality control reviews of documents to ensure accuracy, integrity, and consistency of both data and messaging.

Quality control reviews and/or editorial reviews are performed on any deliverable, in any therapeutic area, using either client checklists or our internal document-specific checklists to ensure the quality and consistency both within and across documents.

Professional medical editors conversing around table.

Quality Control Review:
Data Verification

ProPharma QC reviewers/editors provide 100% source verification of all data in both document text and in-text tables, as necessary. Data verification review is offered in addition to editorial review or as a standalone service.

Editorial Review:
No Data Verification

ProPharma QC reviewers/editors provide a complete editorial review to ensure consistency, clarity of message, and appropriate implementation of style and template requirements. Editorial review includes general copy editing and review of abbreviations, internal cross references, and citations, and is offered in addition to data verification review or as a standalone service.


Benefits of Working with Our Quality Control Review/Editing Team

Global submission icon

GLOBAL AND EXPERIENCED

ProPharma QC reviewers/editors are located across North America, Europe, and India. They have an average of 10 years of experience spanning multiple therapy areas and domains.

Full Service Clinical Trials icon

FLEXIBLE AND SCALABLE

With access to a large pool of experienced resources, we are responsive to changes in workload and can scale as needed to accommodate variable client demands and volume.

Compliance

COMPREHENSIVE AND THOROUGH

We perform comprehensive reviews of each document using detailed document-specific checklists to ensure quality and consistency within and across documents.

Quality Control Review Frequently Asked Questions

Click on frequently asked questions about ProPharma's quality control review and editing services to learn about our experience and expertise.

Yes, ProPharma QC reviewers/editors accommodate last-minute and drop-in QC requests as needed.

ProPharma understands that timelines shift, projects get cancelled, and that shifting timelines are a potential risk in any project. ProPharma remains flexible and mitigates this risk through consistent project and resource management. Resource availability and project status are routinely reviewed and updated, allowing us to adapt in real time and overcome any potential challenges, including timeline shifts.

If a project shifts out significantly, we work with clients to map out a plan that ensures both timely delivery and service continuity. We take steps to ensure (to the extent possible) the same person can re-engage on the project once it becomes active again. If timelines accelerate, we can provide additional resources, as needed, to ensure timeline integrity.

ProPharma can utilize either our internal QC SOPs or client SOPs.

Yes. ProPharma has both general and document-specific QC checklists.

Yes, ProPharma QC reviewers/editors provide consistent application of general and/or client-specific style guides (including therapeutic area-specific style guides, as applicable).

Have questions? We'd be happy to talk with you
about your unique needs and goals.

News & Insights

QMSR Explained: Key Changes from FDA QSR to the New Quality Management System Regulation

July 23, 2026

QMSR Explained: Key Changes from FDA QSR to the New Quality Management System Re...

The FDA's transition to the QMSR simplifies compliance, emphasizing risk management and aligning with global standards for medical devices compared to QMR.

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

July 20, 2026

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

Discover effective strategies for building relationships with clinical trial sites to streamline the study start-up process and enhance activation timelines.

FDA Weighs in on Popular Peptides

July 17, 2026

FDA Weighs in on Popular Peptides

FDA is reviewing seven popular peptides for potential inclusion on the 503A Bulks List. Learn what the review means for compounding pharmacies and patient access.

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

News & Insights

QMSR Explained: Key Changes from FDA QSR to the New Quality Management System Regulation

July 23, 2026

QMSR Explained: Key Changes from FDA QSR to the New Quality Management System Re...

The FDA's transition to the QMSR simplifies compliance, emphasizing risk management and aligning with global standards for medical devices compared to QMR.

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

July 20, 2026

Building Relationships with Sites: The Hidden Driver of Faster Start-Ups

Discover effective strategies for building relationships with clinical trial sites to streamline the study start-up process and enhance activation timelines.

FDA Weighs in on Popular Peptides

July 17, 2026

FDA Weighs in on Popular Peptides

FDA is reviewing seven popular peptides for potential inclusion on the 503A Bulks List. Learn what the review means for compounding pharmacies and patient access.

Previous Post Arrow Next Post Arrow
ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

July 8, 2026

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability fo...

ProPharma unveils an AI-assisted capability to enhance ANDA submission development, improving efficiency and maintaining regulatory excellence for clients.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation - ProPharma

July 23, 2026

Inspection-Ready AI: Building Quality Frameworks That Keep Pace with Innovation

As artificial intelligence becomes increasingly embedded across life sciences, organizations face a growing challenge: ensuring quality and compliance frameworks evolve alongside rapidly advancing...

Case Study Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A Regulatory and Pharmacovigilance-Led Solution - ProPharma

July 15, 2026

Ensuring Continuity of Neonatal Vitamin Prophylaxis During a Product Shortage: A...

Product shortages involving essential medicines can create significant clinical and regulatory challenges, particularly when vulnerable patient populations depend on uninterrupted access to...

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Previous Resource Arrow Next Resource Arrow
Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

June 4, 2026

Tech Meets Touch: Evaluating Empathy and AI in Medical Information Delivery

Artificial intelligence (AI) is a hot topic in Medical Information (MI), yet real-world evidence of its impact in regulated, human-led MI environments remains limited. Hear practical, evidence-based...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

Previous Webinar Arrow Next Webinar Arrow